• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Henry Schein Inc.

    12/13/24 8:56:07 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    S-8 1 d865020ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on December 13, 2024

    Registration No. 333-________

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    HENRY SCHEIN, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware
       11-3136595

    (State or other jurisdiction of

    incorporation or organization)

      

    (I.R.S. Employer

    Identification No.)

    135 Duryea Road

    Melville, New York

       11747
    (Address of Principal Executive Offices)    (Zip code)

    Henry Schein, Inc. Deferred Compensation Plan

    (as amended and restated effective as of November 14, 2023)

    (Full title of the plan)

    Kelly Murphy, Esq.

    Senior Vice President and General Counsel

    Henry Schein, Inc.

    135 Duryea Road

    Melville, New York 11747

    (Name and address of agent for service)

    631-843-5500

    (telephone number, including area code, of agent for service)

     

     

    Copies of all communications to:

    Michael E. Ellis, Esq.

    Proskauer Rose LLP

    Eleven Times Square

    New York, New York 10036

    212-969-3000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This registration statement relates to the registration of $150,000,000 in unsecured obligations of Henry Schein, Inc. to pay deferred compensation in the future in accordance with the terms of the Henry Schein, Inc. Deferred Compensation Plan, as amended and restated effective as of November 14, 2023, and as subsequently amended.

    Pursuant to General Instruction E to Form S-8, the following registration statement on Form S-8 previously filed by the Company with the Securities and Exchange Commission (the “SEC”) is incorporated by reference into this registration statement, except as the same may be modified by the information set forth herein:

     

    File No.

      

    Date

    333-171400    December 23, 2010


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

     

    Exhibit

    Number

      

    Description

      4.1    Second Amended and Restated Certificate of Incorporation of Henry Schein, Inc. (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on June 1, 2018)
      4.2    Fourth Amended and Restated By-Laws of Henry Schein, Inc. (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on March 24, 2023)
      5.1    Opinion of Proskauer Rose LLP*
     23.1    Consent of BDO USA, P.C.*
     23.2    Consent of Proskauer Rose LLP (included in Exhibit 5.1)*
     24.1    Powers of Attorney (included on signature page)
     10.1    Henry Schein, Inc. Deferred Compensation Plan, as amended and restated effective as of November  14, 2023. (Incorporated by reference to Exhibit 10.1 to our Current Report on For 8-K filed on November 16, 2023)
    107    Filing Fee Table*

     

    *

    filed herewith

     

    1


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Melville, State of New York, on December 13, 2024.

     

    HENRY SCHEIN, INC.
    By:  

    /s/ Stanley M. Bergman

      Name:   Stanley M. Bergman
      Title:   Chairman and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Stanley M. Bergman and Ronald N. South, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, to act, without the other, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Henry Schein, Inc., and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed on December 13, 2024, by the following persons in the capacities indicated:

     

    Signatures

      

    Title

    /s/ Stanley M. Bergman

    Stanley M. Bergman

      

    Chairman and Chief Executive Officer (Principal Executive Officer)

    /s/ Ronald N. South

    Ronald N. South

       Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

    /s/ Mark E. Mlotek

    Mark E. Mlotek

      

    Director, Executive Vice President and Chief Strategic Officer

    /s/ Mohamad Ali

    Mohamad Ali

      

    Director


    /s/ Deborah Derby

    Deborah Derby

      

    Director

    /s/ Carole T. Faig

    Carole T. Faig

      

    Director

    /s/ Joseph L. Herring

    Joseph L. Herring

      

    Director

    /s/ Kurt P. Kuehn

    Kurt P. Kuehn

      

    Director

    /s/ Philip A. Laskawy

    Philip A. Laskawy

      

    Director

    /s/ Anne H. Margulies

    Anne H. Margulies

      

    Director

    /s/ Carol Raphael

      

    Director

    Carol Raphael   

    /s/ Scott Serota

      

    Director

    Scott Serota   

    /s/ Bradley T. Sheares, Ph.D.

    Bradley T. Sheares, Ph.D.

      

    Director

    /s/ Reed V. Tuckson, M.D., FACP

      

    Director

    Reed V. Tuckson, M.D., FACP   
    Get the next $HSIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    2/26/2024$78.00Market Perform
    Leerink Partners
    12/12/2023$71.00 → $82.00Neutral → Overweight
    JP Morgan
    11/10/2023$70.00Hold → Buy
    Stifel
    8/8/2022$80.00Sell → Neutral
    UBS
    More analyst ratings

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      11/13/24 3:30:01 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Henry Schein Inc.

      SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

      11/12/24 9:32:27 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      2/14/24 11:18:57 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Henry Schein with a new price target

      Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00

      2/14/25 7:05:26 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein upgraded by BofA Securities with a new price target

      BofA Securities upgraded Henry Schein from Underperform to Buy and set a new price target of $84.00 from $69.00 previously

      1/6/25 8:12:21 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Mizuho initiated coverage on Henry Schein with a new price target

      Mizuho initiated coverage of Henry Schein with a rating of Neutral and set a new price target of $75.00

      12/4/24 7:41:29 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Henry Schein Inc.

      SCHEDULE 13D/A - HENRY SCHEIN INC (0001000228) (Subject)

      5/6/25 4:15:28 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Henry Schein Inc.

      10-Q - HENRY SCHEIN INC (0001000228) (Filer)

      5/5/25 1:41:33 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HENRY SCHEIN INC (0001000228) (Filer)

      5/5/25 6:14:20 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    See more

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Give Kids A Smile Program Celebrates 23rd Year of Providing Free Oral Health Care Services to Underserved Children

      The American Dental Association Foundation's Initiative, with Exclusive National Sponsors Henry Schein and Colgate-Palmolive, Continues to Expand Its Reach, With Nearly 325,500 Children Expected to Receive Care Throughout 2025 The American Dental Association Foundation (ADA Foundation) is celebrating the 23rd year of its Give Kids A Smile® (GKAS) program, which officially launched on Friday, February 7, at the 2025 national kick-off event at Meharry Medical College School of Dentistry. Since its national launch in 2003, GKAS volunteers have provided free oral health education and services to more than 9.5 million underserved children in the U.S. This press release features multimedia. Vi

      2/10/25 6:30:00 AM ET
      $CL
      $HSIC
      Package Goods/Cosmetics
      Consumer Discretionary
      Medical Specialities
      Health Care
    • Henry Schein to Participate in Upcoming Investor Conferences in May

      Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conferences in May: Bank of America Healthcare Conference at the Encore Hotel in Las Vegas on May 14, 2025, at 10:00 a.m. Pacific time (1:00 p.m. Eastern time). Stifel Jaws & Paws Conference at Lotte Hotel, New York City, on May 29, 2025, at 12:40 p.m. Eastern time. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc

      5/6/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Reports First Quarter 2025 Financial Results

      First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

      5/5/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Medical Announces Winner of Its 2025 Rising Star Award

      Fifth Annual Award Spotlights Up-and-Coming Athletic Trainers Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (NASDAQ:HSIC), announced today that Ian Jeffer, MS, ATC, LAT, Head Athletic Trainer at Desert Ridge High School in Mesa, Arizona, is the winner of the fifth annual Henry Schein Medical Athletics and Schools Rising Star Award. The recognition celebrates emerging athletic trainers with up to five years of experience in the Sports Medicine industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250418934421/en/From left to right: Ian Jeffer, Marissa Lucas, and Angel Picart. Mr. Jeffer was recognized f

      4/22/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Lin Max claimed no ownership of stock in the company (SEC Form 3)

      3 - HENRY SCHEIN INC (0001000228) (Issuer)

      5/8/25 4:10:36 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Director Laskawy Philip A sold $184,999 worth of shares (2,604 units at $71.04), decreasing direct ownership by 10% to 24,805 units (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      3/20/25 4:28:08 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • EVP & Chief Operating Officer Ettinger Michael S gifted 455 shares, decreasing direct ownership by 0.44% to 103,693 units (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      3/20/25 4:24:09 PM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Financials

    Live finance-specific insights

    See more
    • Henry Schein Reports First Quarter 2025 Financial Results

      First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

      5/5/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on

      4/8/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Detailed 2025 Financial Guidance

      Fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19 Fourth-quarter 2024 operating cash flow of $204 million; full-year 2024 operating cash flow of $848 million, up $348 million compared with 2023 2025 non-GAAP diluted EPS expected to be in the range of $4.80 to $4.94 with mid-single digit 2025 Adjusted EBITDA growth Announces new reportable segments to provide more meaningful information for investors Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter and full year ended December 28, 2024. The financial result

      2/25/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care